NorthWest Biotherapeutics Inc (NWBO)

[Dan88]

Regards DNDN, manufacturing was indeed a problem, so was insurance coverage, ill-planning and implementation, etc., though not the critical one, as many have pointed out.

Its sale of provenge was and has been terrible, chiefly because its meager benefits and high costs on the backdrop of cheap, more affordable and easy to manage competing therapy, which was just approved around the same time as DNDN.

Simply there are too many reasons, and I am happy to see LP has learnt some lessons which might affect us, but in any circumstance, DCvax and Provenge are a huge gorge difference in many ways.